Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China.

Nie, Jing; Wu, Huina; Sun, Lei; Ding, Yanjiao; Luan, Yepeng; Wu, Jiyong

Nie, Jing; Wu, Huina; Sun, Lei; Ding, Yanjiao; Luan, Yepeng; Wu, Jiyong.

Afiliación

Nie J; Department of Pharmacy, Shandong Second Provincial General Hospital, Jinan, Shandong, China.
Wu H; Department of Pharmacy, Shandong Second Provincial General Hospital, Jinan, Shandong, China.
Sun L; Department of Pharmacy, Shandong Second Provincial General Hospital, Jinan, Shandong, China.
Ding Y; Department of Pharmacy, Shandong Second Provincial General Hospital, Jinan, Shandong, China.
Luan Y; Department of Medicinal Chemistry, School of Pharmacy, Qingdao University Medical College, Qingdao University, Qingdao, Shandong, China.
Wu J; Department of Pharmacy, Shandong Second Provincial General Hospital, Jinan, Shandong, China.

Front Pharmacol ; 13: 987337, 2022.

Article en En | MEDLINE | ID: mdl-36686677

Palabras clave

BRCA1/2 mutation; cost-effectiveness; fuzuloparib; maintenance treatment; niraparib; olaparib; ovarian cancer

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 Problema de salud: 1_financiamento_saude Tipo de estudio: Clinical_trials / Diagnostic_studies / Health_economic_evaluation / Screening_studies Aspecto: Patient_preference Idioma: En Revista: Front Pharmacol Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google